A Osterborg

Summary

Country: Sweden

Publications

  1. ncbi Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
    A Osterborg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    J Clin Oncol 15:1567-74. 1997
  2. ncbi Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
    P Kokhaei
    Immune and Gene Therapy Lab, CCK, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:1810-5. 2004
  3. ncbi Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    E D Rossmann
    Department of Oncology (Radiumhemmet, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Hematol J 2:300-6. 2001
  4. ncbi Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production
    L Adamson
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Stockholm, Sweden
    Scand J Immunol 69:529-36. 2009
  5. ncbi Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
    M R Rezvany
    Immune and Gene Therapy Laboratory CCK, Karolinska Hospital, Stockholm, Sweden
    Br J Haematol 115:263-71. 2001
  6. ncbi Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
    J Lundin
    1Department of Haematology, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:484-90. 2004
  7. ncbi T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
    J Fagerberg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Int J Cancer 80:671-80. 1999
  8. ncbi Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
    Q Yi
    Immunological Research Laboratory, Karolinska Hospital, Stockholm, Sweden
    Blood 92:402-4. 1998
  9. ncbi Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
    A Osterborg
    Department of Oncology, Radiumhemmet and Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 39:797-800. 2000
  10. ncbi Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
    A O Abdalla
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Stockholm, Sweden
    Ann Oncol 19:1172-9. 2008

Collaborators

Detail Information

Publications27

  1. ncbi Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
    A Osterborg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    J Clin Oncol 15:1567-74. 1997
    ..We report the results of a multicenter phase II trial that used CAMPATH-1H in previously chemotherapy-treated patients with chronic lymphocytic leukemia (CLL)...
  2. ncbi Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
    P Kokhaei
    Immune and Gene Therapy Lab, CCK, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:1810-5. 2004
    ..Our data suggest that cellular vaccines with DC loaded with apoptotic bodies may be a suitable approach for immunotherapy of B-CLL...
  3. ncbi Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
    E D Rossmann
    Department of Oncology (Radiumhemmet, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Hematol J 2:300-6. 2001
    ..Caution must be taken when interpreting in vitro results on cytokine-mediated receptor intensity up-regulation...
  4. ncbi Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production
    L Adamson
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska, Stockholm, Sweden
    Scand J Immunol 69:529-36. 2009
    ....
  5. ncbi Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
    M R Rezvany
    Immune and Gene Therapy Laboratory CCK, Karolinska Hospital, Stockholm, Sweden
    Br J Haematol 115:263-71. 2001
    ..The mechanisms behind the observed increase in some surface molecules and the abnormal cytokine profile of CLL DC is not clear but might indicate pre-activation of DC in vivo, which may have a regulatory role in the pathobiology of CLL...
  6. ncbi Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
    J Lundin
    1Department of Haematology, Karolinska Hospital, Stockholm, Sweden
    Leukemia 18:484-90. 2004
    ..These subpopulations declined gradually during unmaintained follow-up. The relationship between these observations and the safety/antitumour effects of alemtuzumab is discussed...
  7. ncbi T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
    J Fagerberg
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Int J Cancer 80:671-80. 1999
    ..Such T cells could be an important part of the specific anti-tumor immune responses induced in idiotype vaccination protocols...
  8. ncbi Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
    Q Yi
    Immunological Research Laboratory, Karolinska Hospital, Stockholm, Sweden
    Blood 92:402-4. 1998
    ..This study also suggests that KSHV/HHV-8 is not regularly associated with MM and consequently does not play a primary role in the pathogenesis of these tumors...
  9. ncbi Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
    A Osterborg
    Department of Oncology, Radiumhemmet and Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 39:797-800. 2000
    ..The use of GM-CSF seems to be mandatory for the frequency and magnitude of the induced T-cell response. The optimal route, schedule and cytokine combination for idiotype immunization remains to be established...
  10. ncbi Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
    A O Abdalla
    Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Stockholm, Sweden
    Ann Oncol 19:1172-9. 2008
    ..Circulating myeloma cells (CMC), exhibiting the same immunoglobulin heavy-chain gene rearrangements as the plasma cells, are part of the myeloma clone. In this study, we evaluated the effect of idiotype (Id) vaccination on CMC...
  11. ncbi Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
    P Kokhaei
    Immune and Gene Therapy Lab, CCK, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
    Cytotherapy 8:318-26. 2006
    ..Moreover, Ag-loaded DC can be cryopreserved and recovered without significant change in phenotype or function...
  12. ncbi Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
    A Olsson
    Department of Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
    Br J Cancer 97:769-77. 2007
    ..Specific downregulation of bfl-1 using siRNA induced apoptosis in resistant cells. Our data suggest that bfl-1 contributes to chemoresistance and might be a therapeutic target in B-CLL...
  13. ncbi The biology and treatment of chronic lymphocytic leukemia
    M Palma
    Department of Hematology, Cancer Centre Karolinska, Karolinska University Hospital, Stockholm, Sweden
    Ann Oncol 17:x144-54. 2006
  14. ncbi Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
    A Olsson
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Leukemia 15:1868-77. 2001
    ..In addition, neither decoy receptors nor Bcl-2 expression were affected by Act D. Our findings suggest the possible involvement of FLIP in regulating TRAIL-mediated apoptosis in B-CLL...
  15. ncbi Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
    H Mellstedt
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Hematol 6:169-75. 1999
    ..It is urgently warranted to better understand these dual effects on the immune system so that we can find optimal uses for the growth factors in various clinical settings...
  16. ncbi Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)
    H Mellstedt
    Department of Oncology, Karolinska Hospital, Stockholm, Sweden
    Acta Oncol 30:923-31. 1991
    ..The combination of MAb17-1A + GM-CSF augmented the ADCC activity of blood mononuclear cells and a heavy infiltration of monocytes could be noted in the tumor. Out of 15 available patients 6 (40%) showed a response...
  17. ncbi Predominant T cell receptor V gene usage in patients with abnormal clones of B cells
    C H Janson
    Department of Immunology, Karolinska Institute, Stockholm, Sweden
    Blood 77:1776-80. 1991
    ..T- and B-cell populations are normally clonally linked in regulatory circuits. An abnormal proliferation of B cells might therefore induce, or be regulated by, an expansion of clonal T cells, as suggested by the present results...
  18. ncbi Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR
    A O Abdalla
    Immune and Gene Therapy Lab, CCK, Karolinska Hospital, Stockholm, Sweden
    Scand J Immunol 58:601-6. 2003
    ..Granzyme B should preferentially be measured after 48-72 h of activation...
  19. ncbi The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
    M Hassan
    Karolinska Pharmacy, Stockholm, Sweden
    Eur J Haematol 63:163-70. 1999
    ....
  20. ncbi Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
    A Osterborg
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Leukemia 23:1980-8. 2009
    ....
  21. ncbi Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma
    C Zheng
    Division of Haematology, and Immunological Research Laboratory, Centre for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
    Br J Haematol 109:39-45. 2000
    ..Our results indicate that the cytokine (IL-6, TNF-alpha and IL-1beta) and IL-Ra gene polymorphisms do not confer susceptibility to the development of MM...
  22. ncbi Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden
    A Osterborg
    Department of Oncology, Karolinska Hopital, Stockholm, Sweden
    Acta Oncol 29:727-31. 1990
    ..Since intravenous administration of melphalan did not result in a substantial increase in response rate or survival, this study supports the use of oral melphalan/prednisone as first-line therapy for patients with multiple myeloma...
  23. ncbi Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
    A H Daneshmanesh
    Immune and Gene Therapy Lab, CCK, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
    Leukemia 26:1348-55. 2012
    ..The identified ROR1 epitopes may provide a basis for generating human ROR1 MAbs for therapy...
  24. ncbi Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
    R F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden
    Scand J Rheumatol 33:423-7. 2004
    ..The monoclonal anti-B cell antibody rituximab (Rituxin, Mabthera) may be of benefit in antibody-driven diseases, including systemic lupus erythematosus (SLE) nephritis...
  25. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
    ..While our review did not address cost benefit evaluations in detail, the consensus is that studies taking into account all real determinants of cost and benefit need to be performed prospectively...
  26. ncbi Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells
    A A Morales
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Leukemia 18:41-7. 2004
    ..We show that Bmf is regulated by transcriptional activation and alternative splicing and conclude that the relative levels of Bmf isoforms may have a role in regulating growth and survival in B cells and leukemic B-CLL cells...
  27. ncbi Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL
    P Kokhaei
    Immune and Gene Therapy Laboratory, CCK, Karolinska Hospital, Stockholm, Sweden
    Leukemia 17:894-9. 2003
    ..05). This study shows that endocytosed apoptotic tumour cells induced a significantly stronger T-cell response than DC hybrids; and as such should be a better candidate for vaccine production...